Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 2 | History Defined

Analyzing Edwards Lifesciences's Short Interest

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 166.36% since its last report. The company recently reported that it has 5.87 million shares sold short, which is 2.85% of all regular shares that are available for trading.

Peering Into Edwards Lifesciences's Recent Short Interest

Peering Into Edwards Lifesciences's Recent Short Interest

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 6.33% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 0.84% of all regular shares that are available for trading.

Here's How Much $1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 16.51% on an annualized basis producing an average annual return of 22.72%. Currently, Edwards Lifesciences has a market capitalization of $55.48 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Abbott Laboratories vs. Edwards Lifesciences: Which Medical Device Stock is a Better Investment?

The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)…

Where Edwards Lifesciences Stands With Analysts

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

If You Invested $100 In Edwards Lifesciences 20 Years Ago, Here's How Much You Would Have Today

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 14.71% on an annualized basis producing an average annual return of 21.87%. Currently, Edwards Lifesciences has a market capitalization of $69.03 billion.

Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

inkl

Read news from The Economist, FT, and more,
with one subscription

Medtronic vs. Edwards Lifesciences: Which Medical Device Stock is a Better Buy?

Medtronic vs. Edwards Lifesciences: Which Medical Device Stock is a Better Buy?

Growing demand from an aging population to track their diseases and increased focus on critical surgical procedures with lesser COVID-19 pressures on hospitals make the medical devices industry’s prospects bright. Moreover, the integration of emerging technologies and continued innovations should drive the industry’s growth. Therefore, prominent players in this space,…

Recap: Edwards Lifesciences Q1 Earnings

Recap: Edwards Lifesciences Q1 Earnings

Edwards Lifesciences (NYSE:EW) reported its Q1 earnings results on Tuesday, April 26, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Expert Ratings for Edwards Lifesciences

Expert Ratings for Edwards Lifesciences

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022

FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery

FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery

The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) Mitris Resilia valve, a tissue valve replacement specifically designed for the heart's mitral position.

What 9 Analyst Ratings Have To Say About Edwards Lifesciences

What 9 Analyst Ratings Have To Say About Edwards Lifesciences

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Analyst Ratings For Edwards Lifesciences

Analyst Ratings For Edwards Lifesciences

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

This Foreboding Sign Looms Over Edwards Lifesciences's Chart

If history is any guide, there may be trouble ahead for shares of Edwards Lifesciences (NYSE:EW). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Where Edwards Lifesciences Stands With Analysts

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Edwards Lifesciences Q4 Earnings Fall Short Of Expectations, Reaffirms FY22 Outlook

Heart device company Edwards Lifesciences Corp (NYSE: EW) posted

Edwards Lifesciences: Q4 Earnings Insights

Edwards Lifesciences (NYSE:EW) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Preview: Edwards Lifesciences's Earnings

Edwards Lifesciences (NYSE:EW) is set to give its latest quarterly earnings report on Wednesday, 2022-01-26. Here's what investors need to know before the announcement. Analysts estimate that Edwards Lifesciences will likely report an Earnings Per Share (EPS) of $0.55.

1 2

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Abbott Laboratories

B of A Securities

Apollo Global Management

Intuitive Surgical

Truist Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

417,771 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play